Copy Number Gains in 11q13 and 8q34 Are Highly Linked to Prognosis in Cutaneous Malignant Melanoma

Journal of Molecular Diagnostics

Volumn 13, Issue 3, 2011, Pages 352-358

  Gerami, Pedram ^a,d   Jewell, Susan S ^d,e   Pouryazdanparast, Pedram ^a   Wayne, Jeffery D ^b   Haghighat, Zahra ^a   Busam, Klaus J ^f,g   Rademaker, Alfred ^c,d   Morrison, Larry ^d,e,h  

^a Departments of Dermatology   (United States)

^b Departments of Surgery   (United States)

^c Departments of Surgery and Preventive Medicine   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Molecular Division   (United States)

^f ABBOTT LABORATORIES   (United States)

^g Abbott Laboratories ^*  (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHROMOSOME 11Q; CHROMOSOME 13; CHROMOSOME 8Q; CLINICAL EVALUATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MECHANICAL PROBE; MELANOMA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PROGNOSIS; SKIN TUMOR; ULCER;

ALIAS;

EID: 79954588619     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2011.01.011     Document Type: Article

References (17)

1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206
2. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastian BC: Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008, 5:e120
3. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac RS, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE: Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008, 26:2046-2051
4. Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA, Demetri GD, Widlund HR, Fisher DE, Hodi FS: Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008, 14: 7726-7732
5. Lutzky J, Bauer J, Bastian BC: Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008, 21:492-493 (Pubitemid 351990966)
6. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D: Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998, 58:2170-2175 (Pubitemid 28232904)
7. Gerami P, Jewell SS, Morrison LE, Blondin B, Schulz J, Ruffalo T, Matushek P 4th, Legator M, Jacobson K, Dalton SR, Charzan S, Kolaitis NA, Guitart J, Lertsbarapa T, Boone S, LeBoit PE, Bastian BC: Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 2009, 33:1146-1156
8. Gerami P, Guitart J, Martini M, Wayne JD, Kuzel T: Cyclin D1 homogeneous staining regions by fluorescent in situ hybridization: a possible indicator of aggressive behavior in melanomas. Arch Dermatol 2008, 144:1235-1236
9. Pouryazdanparast P, Newman M, Mafee M, Guitart J, Gerami P: Malignant melanoma with monster cells showing massive cyclin D1 amplification. Am J Dermatopathol 2009, 31:402-403
10. Tovey SM, Brown S, Doughty JC, Mallon EA, Cooke TG, Edwards J: Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer 2009, 100:680-683
11. Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S: Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2010, 16:291-303
12. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordóñez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, Beare D, Butler A, Carter RJ, Chen L, Cox AJ, Edkins S, Kokko-Gonzales PI, Gormley NA, Grocock RJ, Haudenschild CD, Hims MM, James T, Jia M, Kingsbury Z, Leroy C, Marshall J, Menzies A, Mudie LJ, Ning Z, Royce T, Schulz-Trieglaff OB, Spiridou A, Stebbings LA, Szajkowski L, Teague J, Williamson D, Chin L, Ross MT, Campbell PJ, Bentley DR, Futreal PA, Stratton MR: A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196
13. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC: Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353: 2135-2147 (Pubitemid 41653105)
14. G khale S, Gatalica Z, Mohammad A, Rampy AI, Velagaleti Gopalrao VN. FISH for HER-2/neu in breast cancer: standardization makes the difference! Indian J Cancer 2004, 41:152-158 (Pubitemid 40203358)
15. Kumar V, Cotran R, Robbins S: Basic Pathology, ed 6. Philadelphia, Saunders Co, 1997
16. Brower V: BRAF inhibitors: research accelerates in wake of positive findings. J Natl Cancer Inst 2010, 102:214-215
17. Smalley KS, Flaherty KT: Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Future Oncol 2009, 5:775-778